ArticleDiscover oncology2025
Mendelian randomization analysis reveals causal roles of inflammatory cytokines in thyroid cancer pathogenesis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrated Cytokine, Metabolic, and Proliferative Profiling Reveals Divergent Metabolic and Proliferative Responses in Papillary Thyroid Cancer Cells.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid cancer is a common endocrine malignancy associated with various inflammatory factors. This research aimed to explore the causal relationships between 41 inflammatory factors and the risk of thyroid cancer using Mendelian randomisation (MR) analysis. MR analysis was performed using genetic data from two publicly available European genome-wide association studies (GWAS). Instrumental variables were selected based on single-nucleotide polymorphisms significantly associated with cytokine levels. Causal relationships were assessed using the inverse variance weighted method, with sensitivity analyses to evaluate heterogeneity and pleiotropy. The results suggest that interleukin-1 receptor antagonist (IL-1RA) and β-nerve growth factor (B-NGF) are risk factors for thyroid cancer, while macrophage colony-stimulating factor (M-CSF) has a protective effect. IL-1RA, B-NGF, and M-CSF play a key role in regulating the tumour microenvironment compared with 38 other inflammatory factors that do not show a clear correlation. IL-1RA may promote cancer cell proliferation by activating pro-inflammatory signalling pathways, while B-NGF may enhance angiogenesis and immune escape, accelerating tumour progression. Conversely, M-CSF may reduce thyroid cancer risk by enhancing the anti-tumour immune response. Additionally, single-nucleotide polymorphism survival prognostic analysis showed that specific genetic variants associated with IL-1RA, B-NGF, and M-CSF may influence overall survival (OS) and cancer-specific survival (CSS) in patients with thyroid cancer, further supporting their potential value in thyroid cancer management. These findings suggest that IL-1RA and B-NGF could serve as novel biomarkers for early detection and disease monitoring of thyroid cancer, while M-CSF could be a potential therapeutic target, providing theoretical support for personalised intervention strategies. The results provide a new direction for precision medicine research in thyroid cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.